Radiosensitization by Docetaxel Prodrug-Loaded Lipid Nanoparticles in Pancreatic Cancer Xenografts

TL;DR

Researchers tested a new treatment combining nanoparticles and radiation to improve cancer therapy in pancreatic tumors, showing promising results in reducing tumor size and increasing survival.

Contribution

The study introduces a radiosensitizing strategy using lipid-nanoparticle-encapsulated docetaxel prodrug for pancreatic cancer treatment.

Findings

LNPDTX–P combined with radiation reduced tumor volume by ~40% in xenografts.

The treatment significantly prolonged survival compared to radiation alone (p < 0.001).

Adding gold nanoparticles did not improve efficacy beyond LNPDTX–P and radiation.

Abstract

Cancer treatments are limited by poor tumor specificity and toxicity. We tested a radiosensitizing approach using PEG/RGD-functionalized gold nanoparticles (GNPs), a lipid-nanoparticle–encapsulated docetaxel prodrug (LNPDTX–P), and external-beam radiotherapy (RT). In MIA PaCa-2 xenografts, intravenous GNPs (2 mg/kg) and LNPDTX–P (6 mg/kg) were given before 5 Gy RT. Both LNPDTX–P + RT and GNPs + LNPDTX–P + RT reduced tumor volume by ~40% and significantly prolonged survival versus RT alone (p < 0.001). Adding GNPs did not enhance efficacy, indicating LNPDTX–P was the main driver under this regimen. These results demonstrate nanocarrier-enabled radiosensitization in vivo and support further studies toward clinical translation.

Figures